SCHEMBL6756451

SCHEMBL6756451

CCOC(=O)c1cn(CC)c2c(F)c(F)c(F)cc2c1=O

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 3/20 0.61
KMT2A Q03164 2/20 0.58
TDP1 Q9NUW8 1/20 0.57
ALDH1A1 P00352 6/20 0.56
KDM4E B2RXH2 5/20 0.56
HPGD P15428 5/20 0.56
HSD17B10 Q99714 4/20 0.56
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.52
HTT P42858 2/20 0.50
CYP1A2 P05177 1/20 0.47
ADRB2 P07550 1/20 0.47
PMP22 Q01453 1/20 0.47
TSHR P16473 1/20 0.45
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29895231 1.00 STAT3 (0.61) STAT3KMT2ATDP1ALDH1A1KDM4E
SCHEMBL11229199 0.93 KMT2A (0.56) STAT3KMT2ATDP1ALDH1A1KDM4E
SCHEMBL10459763 0.93 STAT3 (0.56) STAT3KMT2ATDP1ALDH1A1KDM4E
SCHEMBL584246 0.91 STAT3 (0.58) STAT3KMT2ATDP1ALDH1A1KDM4E
SCHEMBL9442764 0.91 LMNA (0.58) STAT3KMT2ATDP1ALDH1A1KDM4E
SCHEMBL9186530 0.90 LMNA (0.57) STAT3KMT2ATDP1ALDH1A1KDM4E
SCHEMBL10766493 0.90 STAT3 (0.54) STAT3KMT2ATDP1ALDH1A1KDM4E
SCHEMBL5258333 0.90 STAT3 (0.62) STAT3KMT2ATDP1ALDH1A1KDM4E
SCHEMBL584797 0.89 STAT3 (0.53) STAT3KMT2ATDP1ALDH1A1KDM4E
SCHEMBL10623495 0.89 KMT2A (0.55) STAT3KMT2ATDP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115703757-B Synthesis method of melaxacin 浙江中欣氟材股份有限公司 2024-04-09 CN claimed
CN-116283766-A Cyanomethyl quinolone compound and preparation method and application thereof 西南大学 2023-06-23 CN claimed
CN-115703757-A Synthesis method of melafloxacin 浙江中欣氟材股份有限公司 2023-02-17 CN claimed
CN-115636785-A Quinolone cyanoacetate compounds and pharmaceutically acceptable salts thereof, and preparation method and application thereof 西南大学 2023-01-24 CN claimed
CN-111208221-B Method for detecting lomefloxacin hydrochloride related substances 宜宾市南溪区红光制药有限公司 2022-07-05 CN claimed
CN-115636785-B Quinolone cyanoacetate compound and pharmaceutically acceptable salt thereof, and preparation method and application thereof 西南大学 2024-05-28 CN disclosed
CN-115703757-B Synthesis method of melaxacin 浙江中欣氟材股份有限公司 2024-04-09 CN disclosed
CN-116283766-A Cyanomethyl quinolone compound and preparation method and application thereof 西南大学 2023-06-23 CN disclosed
CN-115703757-A Synthesis method of melafloxacin 浙江中欣氟材股份有限公司 2023-02-17 CN disclosed
CN-115636785-A Quinolone cyanoacetate compounds and pharmaceutically acceptable salts thereof, and preparation method and application thereof 西南大学 2023-01-24 CN disclosed
CN-111208221-B Method for detecting lomefloxacin hydrochloride related substances 宜宾市南溪区红光制药有限公司 2022-07-05 CN disclosed
CN-111208221-B Method for detecting lomefloxacin hydrochloride related substances 宜宾市南溪区红光制药有限公司 2022-07-05 CN disclosed
US-20040147545-A1 Derivatives of oxazolidinones as antibacterial agents LABORATORIOS VITA, S.A. (ES) 2004-07-29 US disclosed
US-20030181719-A1 Novel heterocyclic antibacterial compounds MICROBIOTIX, INC. 2003-09-25 US disclosed
US-6229017-B1 BY ACYLATION AND CYCLIZATION OF A BENZOYL CHLORIDE OR NICOTINOYL CHLORIDE IN THE PRESENCE OF A NON-POLAR TO SLIGHTLY POLAR SOLVENT WITHOUT SEPARATION OF CHEMICAL INTERMEDIATES DURING PROCESS BAYER AKTIENGESELLSCHAFT (DE) 2001-05-08 US disclosed
US-5753658-A FOR TREATMENT OF BACTERIAL INFECTIONS SENJU PHARMACEUTICAL CO., LTD. (JP) 1998-05-19 US disclosed
EP-0610896-A1 Quinolonecarboxylic acid derivatives as antibacterials Senju Pharmaceutical Co., Ltd. (JP) 1994-08-17 EP disclosed
EP-0140116-B1 A 6-FLUORO-1,4-DIHYDRO-4-OXO-7-SUBSTITUTED PIPERAZINYL-QUINOLINE-3-CARBOXYLIC ACID DERIVATIVE AND THE METHOD FOR PREPARING THE SAME Hokuriku Pharmaceutical Co.,Ltd (JP) 1988-05-25 EP disclosed
US-4528287-A 6-Fluoro-1, 4-dihydro-4-oxo-7-substituted piperazinylquinoline-3-carboxylic acids and the method for preparing the same HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1985-07-09 US disclosed
EP-0140116-A1 A 6-fluoro-1,4-dihydro-4-oxo-7-substituted piperazinyl-quinoline-3-carboxylic acid derivative and the method for preparing the same Hokuriku Pharmaceutical Co.,Ltd (JP) 1985-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181719-A1 Novel heterocyclic antibacterial compounds TOP1, TOP2A, TOP2B STAT3 3898/4885KMT2A 2259/4885TDP1 74/4885
US-20040147545-A1 Derivatives of oxazolidinones as antibacterial agents OXA1L, Q6ZSR9, PGC STAT3 4244/4885KMT2A 3161/4885TDP1 4274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.